For example, it has been shown that knockdown of key components such as ATG7 and p62, sensitizes AML cell lines for combination treatment with a number of different chemotherapeutic drugs (Bosnjak et al., 2014; Piya et al., 2016). This evidence concerns the gene SQSTM1 and acute myeloid leukemia.